How to Help Your Patients Save Money on Zomacton: A Provider's Guide to Savings Programs

For providers prescribing Zomacton (somatropin), the medication's cost is a real barrier for many patients — and one that can lead to delayed treatment initiation, premature discontinuation, or non-adherence. Understanding the financial assistance landscape and proactively connecting patients with savings programs is an essential part of prescribing this medication effectively.

This guide summarizes the key savings programs available for Zomacton in 2026, how to enroll patients, and strategies for reducing out-of-pocket burden — including situations where a formulary alternative might better serve the patient's financial needs.

The Cost Reality: Why Savings Programs Matter

At retail pricing, a single 10 mg Zomacton vial costs approximately $620 to $707. Growth hormone therapy is often long-term — years in pediatric patients, potentially lifelong in adults with GHD — which means the cumulative cost without financial assistance can be prohibitive. Even patients with commercial insurance may face high specialty tier copays of $100 to $500 or more per month, before any copay savings are applied.

Research across specialty biologics consistently shows that high out-of-pocket costs are a leading driver of non-adherence. For a pediatric patient who requires consistent dosing to optimize growth velocity, even a brief lapse in treatment can affect outcomes. Proactive enrollment in savings programs from the start is a clinical imperative, not just administrative convenience.

Ferring's ZOMACTON Patient Support Program (For Uninsured or Underinsured Patients)

Ferring's ZOMACTON Patient Support Program is the primary financial assistance program for eligible patients who are commercially uninsured or have commercial insurance but face high out-of-pocket costs. Key program details:

• Maximum annual benefit: Up to $6,000 per year in out-of-pocket cost reduction
• Eligibility: U.S. residents with a valid Zomacton prescription for an FDA-approved indication who are commercially insured or uninsured. Patient or guardian must be 18 years of age or older.
• Excluded patients: Medicare, Medicaid, TRICARE, CHAMPUS, Medigap, or any state pharmaceutical assistance program beneficiaries; patients whose insurance pays the entire cost
• Geographic restrictions: Void in California and Massachusetts
• Program type: Cost reduction benefit, not insurance. Patient is still responsible for remaining costs and insurance obligations.

How to enroll: Contact Ferring's Zomacton support line at 1-844-567-9501 or visit zomacton.com/savings-and-resources/. Your practice can also initiate enrollment during the prescribing process.

Ferring Copay Savings Program (For Commercially Insured Patients)

For patients with commercial insurance that covers Zomacton, Ferring offers a separate copay savings program:

• Savings: Up to $500 per month for eligible patients with prescription drug coverage
• Available at participating specialty pharmacies — confirm with Ferring that the patient's preferred pharmacy participates
• Not valid for government-insured patients (Medicare, Medicaid, TRICARE)

Best practice: Enroll the patient in this copay card at the time of prescribing — before the prescription reaches the specialty pharmacy. This prevents the patient from being billed the full specialty tier copay on the first fill.

ZoGo Support Services for New Adult Patients

Ferring offers ZoGo support services specifically designed for new adult Zomacton patients. These include:

• Prior authorization navigation assistance for your practice
• Specialty pharmacy routing to preferred Ferring-network pharmacies
• Injection training and device tutorials for patients and caregivers
• Patient financial assistance enrollment coordination

38,004+ patients found their medications in stock

38K+

Find Zomacton In Stock Today →

Prior Authorization: Building a Strong First Submission

A denied prior authorization not only delays treatment — it can disrupt patient momentum and create administrative burden for your practice. Minimizing PA denials is one of the highest-impact things your office can do to protect patient access and reduce overall cost burden (denied PAs often lead to gaps and missed doses, which can require dose adjustment or restabilization).

Elements of a successful first PA submission for Zomacton:

1. GH stimulation test results with peak GH levels (typically <10 ng/mL for pediatric GHD, <5 ng/mL for adult GHD)
2. IGF-1 and IGFBP-3 levels (current and baseline)
3. Condition-specific documentation (karyotype for Turner syndrome, SHOX testing, birth records for SGA)
4. Growth velocity data and height measurements over at least 6 months (for pediatric patients)
5. Prescriber attestation that the dose is within FDA-labeled limits
6. Clinical rationale for Zomacton specifically if the plan's formulary prefers a different somatropin brand (e.g., established stability, needle-free ZOMA-Jet device preference)

When Formulary Alternatives May Better Serve the Patient

In some situations, the most financially responsible recommendation for a patient is to consider a formulary-preferred somatropin brand rather than pursuing a medical exception for Zomacton. Consider this approach when:

• The patient is newly starting growth hormone therapy and has not yet begun Zomacton
• The patient's plan strongly prefers Norditropin or Omnitrope at a much lower copay tier (Tier 1-2 vs. Tier 4)
• The patient is not enrolled in (or not eligible for) Ferring's savings programs
• Cost is the primary driver of non-adherence risk

All FDA-approved somatropin products have equivalent mechanisms of action and comparable clinical outcomes for the shared indications. A switch to Norditropin, Genotropin, or Omnitrope does not represent a clinical compromise.

Skip the calls, skip the stress.

Find Zomacton In Stock Today →

50K+

Medications
Found

99%

Success
Rate

6+

Hours saved
on average

Using medfinder to Reduce Access Friction for Patients

Even with savings programs in place, patients who cannot find Zomacton at a pharmacy experience treatment gaps that can affect outcomes. Recommending medfinder to patients can reduce this friction significantly. medfinder calls pharmacies on behalf of patients and texts them results showing which pharmacies can fill their prescription — reducing the time to treatment and minimizing office call volume from frustrated patients.

Provider Action Checklist: Maximizing Zomacton Affordability for Your Patients

1. Enroll patients in Ferring's copay savings card at the time of prescribing (up to $500/month for commercially insured patients) — call 1-844-567-9501
2. For uninsured/underinsured patients, initiate enrollment in the ZOMACTON Patient Support Program ($6,000/year maximum savings)
3. Submit a comprehensive, complete PA on the first try — use Ferring's PA assistance if needed
4. Check the patient's insurance formulary — if Zomacton is non-preferred and savings programs won't bridge the gap, consider a formulary-preferred somatropin alternative
5. Send the prescription to an in-network specialty pharmacy from the start — avoid retail pharmacy confusion
6. Recommend medfinder to patients who have difficulty locating a stocking pharmacy
7. Counsel patients to request refills 7-10 days before running out to avoid treatment gaps

See also: How to Help Your Patients Find Zomacton In Stock: A Provider's Guide.